reVision Therapeutics, Inc.

Our (re)Vision: Bring impactful ophthalmic medicines to as many patients as possible as quickly as possible. The company is pursuing products that address unmet needs, can be priced for access, and still have substantial commercial potential. reVision Therapeutics, Inc. was founded in 2018 to develop medicines with high disease impact, and rapidly get those medicines to patients. The company prioritizes areas of unmet or poorly met needs in ophthalmic disorders by repurposing approved or rescuing shelved drugs that could change patients’ lives. Repurposing or rescuing drugs allows for faster development at a reduced cost. Our lead program is a product for Stargardt disease, a retinal degenerative disease that often begins in childhood. Our candidate is a repurposed, GRAS (generally recognized as safe) cyclodextrin delivered intravitreally that could work as a first-line therapy or in combination with other products currently in development. It can be developed fast and produced at a relatively low cost. Other targets include a repurposed drug for dry eye disease, a rescued therapy for proliferative vitreoretinopathy, and a combination product to treat intraocular pressure.